Sun Pharmaceutical Industries has posted its financials for the third quarter. During the third quarter, the company has reported net sales / income from operations at Rs 4287 crores, a growth of 50 per cent over same quarter last year. The branded generic sales in India has been reported at Rs 947 crores, up by 20 per cent over Q3 last year.
The US finished dosage sales was at $434 million grew by 57 per cent (in $ terms) over Q3 last year. The international formulation sales outside the US at $84 million which grew by 16 per cent (in $ terms) over same quarter last year. The overall international revenues accounted for more than 75 per cent of total revenues for the quarter. EBITDA has been reported at Rs 1975 crores which grew by 57 per cent; resulting EBITDA margin of 46 per cent, compared to 44 per cent for Q3 last year. The net profit at Rs 1531 crores compared to Rs 881 crores for Q3 last year, up 74 per cent over Q3 last year; resulting margin of 36 per cent.
Dilip Shanghvi, Managing Director, Sun Pharmaceutical Industries said, “Our overall performance reflects the focus on execution of our strategy. We are developing a differentiated and speciality business and continue to evaluate opportunities to enhance our global presence.”
EP News Bureau – Mumbai